We are live on ! Find out more

362 hedge funds and large institutions have $5.5B invested in ResMed in 2016 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 171 increasing their positions, 101 reducing their positions, and 46 closing their positions.

New
Increased
Maintained
Reduced
Closed

69% more repeat investments, than reductions

Existing positions increased: 171 | Existing positions reduced: 101

67% more funds holding in top 10

Funds holding in top 10: 35 (+2)

30% more call options, than puts

Call options by funds: $18.4M | Put options by funds: $14.2M

14% more capital invested

Capital invested by funds: $4.83B → $5.5B (+$671M)

2.28% more ownership

Funds ownership: 59.7%61.98% (+2.3%)

3% less funds holding

Funds holding: 375362 (-13)

20% less first-time investments, than exits

New positions opened: 37 | Existing positions closed: 46

Holders
362
Holders Change
-13
Holders Change %
-3.47%
% of All Funds
9.64%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.13%
New
37
Increased
171
Reduced
101
Closed
46
Calls
$18.4M
Puts
$14.2M
Net Calls
+$4.21M
Net Calls Change
+$4.42M

RMD Hedge Fund Activity: Q2 2016 in Review

362 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in ResMed (RMD) for Q2 2016, worth a combined $5.5B — up 14% from $4.83B a quarter earlier.

Sellers outnumbered buyers: 46 funds closed out of RMD and 37 opened new positions — a net loss of 9 holders — while 101 trimmed existing stakes and 171 added.

The largest buyer was Vanguard Group, adding an estimated $65.7M. The largest seller was American Capital Management, exiting entirely with an estimated $40.1M sold.

  • 362 institutional investors held ResMed (RMD) as of Q2 2016, down from 375 in Q1 2016.
  • Funds reported $5.5B of ResMed stock for Q2 2016, up 14% quarter-over-quarter.
  • 37 funds opened new ResMed positions in Q2 2016 and 46 closed out, a net change of -9 holders.
  • The largest ResMed buyer in Q2 2016 was Vanguard Group, an estimated $65.7M added.
  • The largest ResMed seller in Q2 2016 was American Capital Management, an estimated $40.1M sold.

Based on aggregated 13F filings for Q2 2016.